Clinical Trials
51 trialsPazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
National Cancer Institute (NCI)
STARTRK-2
Hoffmann-La Roche
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
PLANE-PC
University of Michigan Rogel Cancer Center
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
Memorial Sloan Kettering Cancer Center
Lumed
University Hospital, Basel, Switzerland
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
National Cancer Institute (NCI)
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
West China Hospital
ALPHAMEDIX02
Orano Med LLC
DeLLphi-307
Amgen
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
I-MAT
Melanoma and Skin Cancer Trials Limited
COMPETE
ITM Solucin GmbH
GoTHAM
Melanoma and Skin Cancer Trials Limited
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
University Health Network, Toronto
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
M.D. Anderson Cancer Center
Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
MOST-CIRCUIT
Olivia Newton-John Cancer Research Institute
MK-6070-001
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
PELICAN
Imperial College London
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
TaiRx, Inc.
SALUS
Advanced Accelerator Applications
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
NET-PRO
University of Iowa
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
University Health Network, Toronto
Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors
University of Alberta
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
University of Iowa
KEYNOTE 158
Merck Sharp & Dohme LLC
COMPOSE
ITM Solucin GmbH
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Sinotau Pharmaceutical Group
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
University of California, San Francisco
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
University of Iowa
Trinav
Abramson Cancer Center at Penn Medicine
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
Harbour BioMed (Guangzhou) Co. Ltd.
Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors
Latin American Cooperative Oncology Group
RADNET
Uppsala University
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe, Inc.
VISIONARY
Peking University
LUTHREE
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
P-PRRT
CHU de Quebec-Universite Laval
CABONEN
University Medical Center Goettingen
NETest_Sx
Wren Laboratories LLC
Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma
Société Française d'Endoscopie Digestive